Inovio
[stock_market_widget type=”inline-label” template=”indicator” assets=”INO” realtime=”true” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”INO” fields=”market_cap,enterprise_value,pe_ratio,forward_pe_ratio,peg_ratio,price_to_sales_trailing_12_months,price_book,enterprise_revenue,enterprise_ebitda” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”INO” fields=”volume,open,previous_close,range,52_week_range,beta,target_high_price,shares_outstanding,shares_float” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
[stock_market_widget type=”chart” template=”line” assets=”INO” range=”1y” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#000000″ range_selector=”true” axes=”true” cursor=”true” style=”font-size: 14px” api=”yahoo-finance”]
Description
Inovio Pharmaceuticals develops DNA medicines and immunotherapies for cancer and infectious diseases. Its pipeline uses synthetic DNA technologies intended to stimulate targeted immune responses through vaccines, therapeutics, and related delivery systems.
Financial Highlights
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”INO” fields=”profit_margin,operating_margin,return_on_assets,return_on_equity,total_revenue,revenue_per_share,revenue_growth,gross_profit,ebitda,net_income_to_common,quarter_earnings_growth,total_cash,total_cash_per_share,total_debt,operating_cashflow” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
Trading Information
[stock_market_widget type=”list” template=”basic” color=”#000000″ assets=”INO” fields=”52_week_low_change_pct,52_week_high,52_week_low,50_day_average,200_day_average,average_volume,average_volume_10_days,shares_outstanding,shares_float,held_percent_insiders,held_percent_institutions,shares_short,short_ratio,annual_dividend_rate,annual_dividend_yield” realtime=”true” style=”font-size: 14px” api=”yahoo-finance”]
